Gastroesophageal Cancer
Advertisement
Tislelizumab shows significant survival benefits in first-line treatment for gastric and esophageal cancers.
FDA approval of the first and only CLDN18.2-targeted treatment follows two successful phase III clinical trials.
For postoperative morbidity and mortality, surgery alone had the highest probability rate.
FLOT and nivo seems to be associated with improved efficacy, whereas chemo followed by IO therapy is insufficient.
Dr. Janjigian shares an overview of the DESTINY-Gastric03 study and the history of T-Dxd for gastric and GEJ cancers.
Trastuzumab deruxtecan, pembrolizumab, and chemotherapy shows benefits in advanced or metastatic esophageal, gastric, or GEJA
These data may support the approval of pembro plus trastuzumab and chemo in patients with HER2+ metastatic G/GEJ cancer.
Standard treatment for ESCC includes esophagectomy, but the surgery is often linked to complications and reduced QoL.
Researchers noted that CIPN was negatively connected to HRQOL across all therapy groups.
The study compared neoadjuvant doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy plus radiotherapy.
Dr. Joel Rubenstein discusses the recent American Gastroenterological Association guideline on EET for Barrett's esophagus.
The risk of developing esophageal cancer is between 30 and 125 times higher in patients with Barrett's esophagus.
Interleukins can aid in the development of a tumor-directed immune response to improve immunotherapy.
Drs. David H. Ilson and Nataliya Uboha highlight the final OS results of the phase 3 SPOTLIGHT study.
Claudin 18 isoform 2 is an emerging therapeutic target in gastric and gastroesophageal cancers.
qFME with oral administration of bevacizumab-800CW and cetuximab-800CW is feasible, and can shorten procedure time.
Dr. Eng opines on how the ESOPEC study will alter the treatment paradigm for patients with esophageal/GEJ adenocarcinoma.
The trio pondered the evolving landscape of upper GI cancer treatments, particularly in localized and advanced stages.
Switch maintenance may extend the benefits of an initial treatment strategy and can delay clinical deterioration.
Drs. Filippo Pietrantonio and Nataliya Uboha break down the results of the phase 3 ARMANI trial.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.